• Organon expanded its partnership with Samsung Bioepis to secure exclusive commercialization rights in Canada for PYZCHIVA, a Stelara-referencing ustekinumab biosimilar.
• Samsung Bioepis retains responsibility for development, manufacturing, regulatory filings; Organon takes commercial execution in Canada.
• Launch is expected in 2026, adding a sixth product to the companies’ Canadian biosimilar collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260618749080) on June 18, 2026, and is solely responsible for the information contained therein.